Valneva closes ~€84M PIPE led by Frazier Life Sciences
What's the deal? Valneva SE, a French specialty vaccine company, has closed an approximately €84M private placement. The company issued nearly 15.9 million ordinary shares, each with one share warrant attached, at €2.33 per unit. The deal yielded €37M at closing, with up to €47M more if all warrants are exercised.
The PIPE was led by existing investor Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, with new investors including TCGXDealroom has a profile for this one. Try Dealroom →, Deep Track CapitalDealroom has a profile for this one. Try Dealroom →, Cormorant Asset Management, Perceptive Advisors, Vivo Capital, and Samsara BioCapitalDealroom has a profile for this one. Try Dealroom →. Existing investor Nantahala also participated.
Jefferies, TD Cowen, and Stifel served as global coordinators, with Van Lanschot Kempen as joint bookrunner.
Why now? Valneva is advancing a pipeline that includes the only Lyme disease vaccine candidate in late-stage clinical development — a partnership with PfizerDealroom has a profile for this one. Try Dealroom → — and the most clinically advanced Shigella vaccine candidate. Fresh capital helps the company push these programmes forward while it generates revenue from three proprietary travel vaccines already on the market.
What could go wrong? The warrant structure means more than half the total raise depends on future exercise, which is tied to share price performance. If the stock stays below the exercise price, Valneva could miss out on €47M. Vaccine development is also inherently risky: clinical setbacks or regulatory delays could undermine the investment thesis.
The signal: A late-growth-stage European vaccine maker pulling in heavyweight US healthcare funds — Perceptive Advisors, Cormorant Asset Management, Deep Track Capital, and others — underscores that transatlantic investor appetite for infectious-disease platforms remains robust well beyond the pandemic window. The participation of both new and existing specialist life-sciences funds suggests the market sees Valneva's Lyme and Shigella programmes as differentiated bets in a sector where few late-stage candidates compete.
Read more: goodwinlaw.com
